Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24592361 | 0.89 | AR (0.57) | ARKCNH2GRM2BRD4CYP2C9 | |
| SCHEMBL24592309 | 0.88 | AR (0.64) | ARKCNH2GRM2BRD4CYP2C9 | |
| SCHEMBL3068954 | 0.84 | AR (0.72) | ARKCNH2GRM2HTR2ABRD4 | |
| SCHEMBL24592106 | 0.83 | AR (0.45) | ARKCNH2GRM2HTR2APRKCZ | |
| SCHEMBL3075117 | 0.82 | AR (0.70) | ARKCNH2BRD4CYP2C9CYP2C19 | |
| SCHEMBL24592290 | 0.81 | AR (0.62) | ARKCNH2BRD4 | |
| SCHEMBL3066026 | 0.81 | AR (0.73) | ARKCNH2BRD4 | |
| SCHEMBL24592182 | 0.81 | AR (0.66) | ARKCNH2GRM2HTR2ABRD4 | |
| SCHEMBL31247266 | 0.81 | AR (0.51) | ARKCNH2 | |
| SCHEMBL3066724 | 0.80 | AR (0.54) | ARKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114685601-B | Androgen receptor binding molecules and uses thereof | 财团法人工业技术研究院 | 2024-10-18 | — | — | CN | disclosed |
| EP-4023649-A1 | ANDROGEN RECEPTOR BINDING BIFUNCTIONAL MOLECULES | Industrial Technology Research Institute (TW) | 2022-07-06 | — | — | EP | disclosed |
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D (SE) | 2013-08-08 | — | — | US | disclosed |
| EP-2396333-B1 | TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-8258140-B2 | Chemical compounds—643 | ASTRAZENECA AB (SE) | 2012-09-04 | — | — | US | disclosed |
| EP-2396333-A1 | TRIAZOLO [4,3-B]PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | AstraZeneca AB (SE) | 2011-12-21 | — | — | EP | disclosed |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | ASTRAZENECA R&D | 2010-10-21 | — | — | US | disclosed |
| WO-2010092371-A1 | TRIAZOLO [4,3-B] PYRIDAZINE DERIVATIVES AND THEIR USES FOR PROSTATE CANCER | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203714-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | AR 1/4885KCNH2 2070/4885GRM2 2513/4885 |
| US-20100267699-A1 | CHEMICAL COMPOUNDS - 643 | AR, KLK3, ESRRA | AR 1/4885KCNH2 1878/4885GRM2 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.